CeriBell, Inc.

NASDAQ:CBLL

Medical - Devices

Healthcare
$25.63 +1.42%

+$0.25 today

Market cap
$995.34M
Beta
0.84
P/E (TTM)
-10.9
EPS (TTM)
-$1.60
52W Low $10.85High $24.33

Volume 0.41M

Average 0.29M

CBLL Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

CeriBell, Inc.NASDAQ: CBLL

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization declines year over year

Q1 FY2026 depreciation & amortization of $239K fell 28.7% year over year, ahead of the -47.5% change in trailing-twelve-month depreciation & amortization.

Context

  • Depreciation & amortization amounted to 0.8% of revenue in FY2025, down 1.0 pp from a year earlier.
  • Depreciation & amortization increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -28.7% holds above the trailing-twelve-month pace of -47.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$239K+176.1% QoQ
Last fiscal yearDec 2025
-$670K-158.7% YoY
LTMMar 2026
$640K-47.5% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-28.7%——
1 year-158.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
(670K) USD
Year-over-year change
-158.7%

Depreciation & Amortization vs competitors

How CBLL compares with its peers on the latest reported figures

  • CBLL's LTM Mar 2026 depreciation & amortization of $640K is the smallest of the 7 companies compared; the peer median is $1.81M.
  • Its year-over-year change of -47.5% is the lowest of 7, against a peer median of +13.5%.
  • Depreciation & amortization amounts to 0.7% of revenue for CBLL, versus a peer median of 2.5%.
CBLL Competitors Peer median
Depreciation & Amortization for CBLL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LIVNLivaNova PLCLTM Sep 2026$64M +11.3%-10.1%4.2%
STIMNeuronetics, Inc.LTM Mar 2026$3.3M +36.1%+28.1%2.2%
NPCENeuroPace, Inc.LTM Mar 2026$2M +10.6%-13.3%2.0%
BWAYBrainsWay Ltd.LTM Mar 2026$1.61M -12.8%+0.1%2.9%
ECORelectroCore, Inc.LTM Mar 2026$1.53M +24.3%+45.1%4.4%
CVRXCVRx, Inc.LTM Mar 2026$777K +15.6%+22.4%1.3%
CBLLCeriBell, Inc.LTM Mar 2026$640K -47.5%—0.7%
Peer median (excluding CBLL) $1.81M+13.5%+11.3%2.5%

Competitors are the stored peer set for CBLL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(37.16M)(29.46M)(40.46M)(53.41M)
Depreciation & Amortization497K847K1.14M(670K)
Deferred Income Tax0000
Stock-Based Compensation7.93M2.68M5.41M12.22M
Change in Working Capital(3.88M)(3.7M)(3.17M)633K
Accounts Receivables(3.96M)(3.43M)(3.51M)(4.18M)
Inventory(1.9M)(1.79M)(1.07M)(351K)
Accounts Payables124K309K250K1.75M
Other Working Capital1.85M1.22M1.16M3.41M
Other Non-Cash Items621K477K2.03M418K
Operating Cash Flow(32M)(29.16M)(35.04M)(40.81M)
Capital Expenditures(516K)(983K)(1.34M)(767K)
Acquisitions (Net)0000
Purchases of Investments000(210.82M)
Sales of Investments00094.2M
Other Investing Activities(883K)(780K)(258K)(755K)
Investing Cash Flow(1.4M)(1.76M)(1.6M)(118.14M)
Debt Repayment(39K)(3.75M)7.91M0
Common Stock Issued00188.92M5.44M
Common Stock Repurchased0000
Dividends Paid0000
Other Financing Activities154K932K(304K)(386K)
Financing Cash Flow49.81M(2.82M)196.52M5.05M
Effect of Forex Changes0000
Net Change in Cash16.4M(33.74M)159.88M(153.89M)
Free Cash Flow(32.52M)(30.14M)(36.38M)(41.58M)

CeriBell, Inc.

NASDAQ:CBLL

Intrinsic Alpha fair value

Locked

Current Price

$25.63

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.